Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
zigakibart - Anti-APRIL
Company overview
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
> Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
Oncology
Other
Global Health
Abbreviations
References
NCT05852938 BEYOND (CFUB523A12301)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Target Patients
IgA nephropathy
Phase 3
292
Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months ]
Arm 1 Experimental: BION-1301 (Zigakibart) 600mg subcutaneous administration
every 2 weeks for 104 weeks
Arm 2 Placebo Comparator: Placebo subcutaneous administration every 2 weeks
for 104 weeks
Adults with IgA Nephropathy
Readout
Milestone(s)
Publication
2026
TBD
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
55View entire presentation